Plus Therapeutics (NASDAQ:CNSY) Releases Earnings Results, Misses Estimates By $0.35 EPS

Plus Therapeutics (NASDAQ:CNSY) posted its earnings results on Friday. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35), Zacks reports. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%.

Plus Therapeutics Stock Performance

NASDAQ:CNSY traded down $0.02 during midday trading on Friday, hitting $3.68. 95,231 shares of the company traded hands, compared to its average volume of 306,130. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.42. The firm has a market capitalization of $25.33 million, a PE ratio of -1.60 and a beta of 1.42.

Analysts Set New Price Targets

CNSY has been the subject of several research reports. Zacks Research lowered shares of Plus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Weiss Ratings started coverage on shares of Plus Therapeutics in a research report on Tuesday, August 4th. They set a “sell (e+)” rating on the stock. Two equities research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.